Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 15/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.40 |
| ▸ | GABRR1 | P24046 | 3/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.40 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.40 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4717853 | 0.78 | NAMPT (0.42) | NAMPT | |
| SCHEMBL4761347 | 0.77 | NAMPT (0.43) | NAMPT | |
| Hydrochloric Acid SCHEMBL4760424 | 0.77 | NAMPT (0.43) | NAMPTPRMT5WDR77 | |
| SCHEMBL4760969 | 0.77 | NAMPT (0.48) | NAMPT | |
| SCHEMBL4717646 | 0.76 | NAMPT (0.47) | NAMPT | |
| SCHEMBL14222058 | 0.75 | NAMPT (0.46) | NAMPTPRMT5WDR77 | |
| SCHEMBL4717310 | 0.75 | KEAP1 (0.50) | NAMPT | |
| SCHEMBL4761797 | 0.75 | ITGB3 (0.53) | NAMPT | |
| SCHEMBL4760017 | 0.75 | ITGB3 (0.54) | NAMPT | |
| SCHEMBL4789267 | 0.75 | NAMPT (0.46) | NAMPTPRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| US-6514964-B1 | Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors | AMGEN INC. | 2003-02-04 | — | — | US | disclosed |